Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells $97,715.48 in Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) insider Francesca Barone sold 13,534 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $97,715.48. Following the sale, the insider now directly owns 110,673 shares in the company, valued at approximately $799,059.06. The trade was a 10.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Francesca Barone also recently made the following trade(s):

• On Wednesday, January 8th, Francesca Barone sold 13,673 shares of Candel Therapeutics stock. The shares were sold at an average price of $8.22, for a total transaction of $112,392.06.

Candel Therapeutics Stock Performance

CADL opened at $6.66 on Monday. Candel Therapeutics, Inc. has a 1 year low of $1.16 and a 1 year high of $14.60. The company’s 50 day simple moving average is $6.61 and its 200 day simple moving average is $6.28. The stock has a market capitalization of $216.32 million, a PE ratio of -3.85 and a beta of -1.20.

Institutional Trading of Candel Therapeutics

Several institutional investors have recently made changes to their positions in CADL. Point72 DIFC Ltd purchased a new position in shares of Candel Therapeutics in the 2nd quarter worth about $31,000. FMR LLC acquired a new stake in Candel Therapeutics during the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC purchased a new position in Candel Therapeutics in the third quarter valued at approximately $87,000. Atom Investors LP acquired a new position in Candel Therapeutics during the third quarter valued at approximately $103,000. Finally, Rhumbline Advisers acquired a new stake in shares of Candel Therapeutics in the second quarter worth $143,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $19.00 target price (up previously from $11.00) on shares of Candel Therapeutics in a research report on Wednesday, December 18th.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.